Dana Conner, MD
Undersea and Hyperbaric Medicine · Blairsville, GANPI 1356344048
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 250 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Melinta Therapeutics, LLC at 53.0% of the total. Reporting peaked in 2021 at $784 and has fallen 53.4% since, to $365 in 2025.
Across 250 payments — averaging $14.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Melinta Therapeutics, LLC$2K
- Paratek Pharmaceuticals, Inc.$566
- Smith+Nephew$280
- Polymedics Innovations Inc.$133
- Hydrofera LLC$84
- Organogenesis Inc.$81
- plus $573 from 19 others
What the payments were for
- Food & beverage$3,54997%
- Education$1033%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Melinta Therapeutics, LLC | 151 | $1,935 |
| Paratek Pharmaceuticals, Inc. | 37 | $566 |
| Smith+Nephew | 18 | $280 |
| Polymedics Innovations Inc. | 3 | $133 |
| Hydrofera LLC | 4 | $84 |
| Organogenesis Inc. | 4 | $81 |
| Solventum Corporation | 3 | $71 |
| Convatec Inc. | 4 | $66 |
| Kerecis Limited | 2 | $56 |
| Reapplix Inc. | 3 | $42 |
| ETS Wound Care LLC | 4 | $35 |
| Johnson & Johnson | 1 | $32 |
| Reprise Biomedical, Inc. | 2 | $31 |
| AbbVie | 2 | $31 |
| Tenex Health Inc. | 1 | $27 |
| Integra Lifesciences Corporation | 2 | $25 |
| Bioventus LLC | 1 | $20 |
| Mimedx Group, Inc. | 1 | $20 |
| Molnlycke Health Care US, LLC | 1 | $19 |
| Hollister Incorporated | 1 | $19 |
| Krystal Biotech Inc | 1 | $19 |
| Misonix Inc | 1 | $18 |
| Reddress USA, Inc. | 1 | $16 |
| Shionogi Inc | 1 | $15 |
| KCI USA, Inc. | 1 | $14 |
How this compares
Too few undersea and hyperbaric medicine providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuzyraOmadacycline Tosylate | 38 | $246,060 |
| Tobramycin Sulfate | 38 | $74,692 |
| Linezolid | 35 | $3,815 |
| Meropenem | 12 | $3,280 |
| Daptomycin | 13 | $2,716 |
| Vancomycin Hcl | 15 | $2,476 |
| CeftriaxoneCeftriaxone Sodium | 11 | $1,425 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 11 | $995 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 60 | $490 |
| Doxycycline Hyclate | 45 | $425 |
| Levofloxacin | 74 | $366 |
| Mupirocin | 12 | $141 |
| Ciprofloxacin Hcl | 17 | $128 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 22 | $98 |
| Prednisone | 20 | $75 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Paratek Pharmaceuticals, Inc.Nuzyra | $566 | $246,06038 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few undersea and hyperbaric medicine providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Other undersea and hyperbaric medicine in Blairsville
- Belinda MarcusNewnan$26K
- Norman McCullochWinder$2K
- Ricardo DuranRoswell$2K
- William LagalyAthens$2K
- Jose GomezCalhoun$1K
- Daniel BelessSandy Springs$955
- John SpenceVidalia$569
- John McGlynnMarietta$456
- Helen GellyMarietta$439
- Martin LynchRome$419
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.